Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Gains from Investment Securities (2016 - 2025)

Guided Therapeutics' Gains from Investment Securities history spans 15 years, with the latest figure at $3.1 million for Q2 2025.

  • For Q2 2025, Gains from Investment Securities rose 51079.92% year-over-year to $3.1 million; the TTM value through Jun 2025 reached $3.1 million, up 833.37%, while the annual FY2024 figure was $2.9 million, 23.3% up from the prior year.
  • Gains from Investment Securities for Q2 2025 was $3.1 million at Guided Therapeutics, up from $2.9 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $3.1 million in Q2 2025 and bottomed at -$151000.0 in Q2 2022.
  • The 5-year median for Gains from Investment Securities is $20500.0 (2021), against an average of $857021.2.
  • The largest annual shift saw Gains from Investment Securities tumbled 15200.0% in 2022 before it soared 233763.6% in 2023.
  • A 5-year view of Gains from Investment Securities shows it stood at $34000.0 in 2021, then skyrocketed by 864.71% to $328000.0 in 2022, then skyrocketed by 613.0% to $2.3 million in 2023, then crashed by 99.7% to $7000.0 in 2024, then skyrocketed by 43768.5% to $3.1 million in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Gains from Investment Securities are $3.1 million (Q2 2025), $2.9 million (Q1 2025), and $7000.0 (Q4 2024).